ICM
PCRX icon

III Capital Management’s Pacira BioSciences PCRX Stock Holding History

III Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-6,243
Closed -$476K – 181
2022
Q1 		$476K Buy
+6,243
New +$416K 0.04% 109
2021
Q4 		– Sell
-14,000
Closed -$784K – 179
2021
Q3 		$784K Buy
+14,000
New +$807K 0.05% 96

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

III Capital Management's PCRX Position: Q2 2022 in Review

III Capital Management sold out of Pacira BioSciences (PCRX) in Q2 2022, closing a stake of 6,243 shares — an estimated $476K sold.

III Capital Management first reported a position in PCRX in Q3 2021 and held it in 2 quarters. The position peaked at $784K in Q3 2021. 284 funds tracked by Wall St. Rank hold PCRX as of Q2 2022.

  • III Capital Management reported no remaining Pacira BioSciences position as of Q2 2022 after selling out during the quarter.
  • III Capital Management sold 6,243 Pacira BioSciences shares in Q2 2022, an estimated $476K.
  • III Capital Management first reported a position in Pacira BioSciences in Q3 2021 and held it in 2 quarters.
  • III Capital Management's Pacira BioSciences position peaked at $784K in Q3 2021.
  • 284 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2022.

Based on III Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.